Introduction: In recent years, concerns about the use of antipsychotic medications in dementia have grown. There is limited data on mortality risk of atypical antipsychotics for other psychiatric disorders of later life such as bipolar disorder. Methods: Data were derived from the national Department of Veterans Affairs registries for older patients with bipolar disorder (>65 years) with a new start of an atypical antipsychotic (risperidone, olanzapine, or quetiapine) or valproic acid and derivatives during fiscal years 2001-2008. Six-month mortality rates were compared for individual drug groups. Results: The sample included 4717 patients. The risperidone cohort had the highest mortality rate (11.8 per 100 person-years) with the quetiapine and valproic acid cohorts having the lowest (5.3 and 4.6 per 100 person-years, respectively). Various methods to adjust for baseline differences including propensity models showed similar patterns. Conclusions: Among older patients with bipolar disorder, there may be differences in mortality risks among individual antipsychotic agents.
MeeksS. Bipolar disorder in the latter half of life: symptom presentation, global functioning and age of onset. J Affect Disord. 1999;52(1-3):161–167.
2.
BartelsSJForesterBMilesKMJoyceT. Mental health service use by elderly patients with bipolar disorder and unipolar major depression. Am J Geriatr Psychiatry. 2000;8(2):160.
3.
YoungRCKlermanGL. Mania in late life: focus on age at onset. Am J Psychiatry. 1992;149(7):867.
SajatovicMBlowFCIgnacioRVKalesHC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr Serv. 2004;55(9):1014–1021.
6.
AzizRLorbergBTampiRR. Treatments for late-life bipolar disorder. Am J Geriatr Pharmacother. 2006;4(4):347–364.
7.
SajatovicMCalabreseJRMullenJ. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord. 2008;10(6): 662–671.
8.
SajatovicMGyulaiLCalabreseJRMaintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry. 2005;13(4):305.
9.
US Food and Drug Administration. Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances, in Public Health Advisory. US Department of Health and Human Services; 2005.
10.
Transcript for FDA Media Briefing on Safety Labeling Changes for Antipsychotic Drugs;2008.
11.
KalesHCKimHMZivinKRisk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71–79.
12.
CharlsonMEPompeiPAlesKLMacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
13.
AdamisDTreloarAMartinFCMacdonaldAJ. Recovery and outcome of delirium in elderly medical inpatients. Arch Gerontol Geriatr. 2006;43(2):289–298.
14.
KalesHCKamholzBAVisnicSGBlowFC. Recorded delirium in a national sample of elderly inpatients: potential implications for recognition. J Geriatr Psychiatry Neurol. 2003;16(1):32–38.
15.
KalesHCZivinKKimHMTrends in Antipsychotic Use in Dementia 1999-2007. Arch Gen Psychiatry. 2011;68:190–197.
16.
SchneeweissSSetoguchiSBrookhartADormuthCWangPS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–632.
17.
WangPSSchneeweissSAvornJRisk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–2341.
18.
SchneiderLSDagermanKSInselP. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943.
19.
RosenbaumPRRubinDB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
20.
KalesHCValensteinMKimHMMortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568–1576.
21.
KimHMChiangCKalesHC. After the black box warning: predictors of psychotropic treatment choices for patients with dementia. Psychiatr Serv. 2011;62(10):1207–1214.
22.
VigenCLPMackWJKeefeRSECognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168:831–839.
BallardCHanneyMTheodoulouMThe dementia antipsychotic withdrawal trial (DART-AD): long-term follow- up of a randomised placebo-controlled trial.Lancet Neurol.2009;8(2):151–157.
